|
1
|
Parkin DM, Bray F, Ferlay J, et al: Global
cancer statistics 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Lazzeroni M and Decensi A: Breast cancer
prevention by antihormones and other drugs: where do we stand?
Hematol Oncol Clin North Am. 27:657–672. 2013. View Article : Google Scholar
|
|
3
|
Singel SM, Cornelius C, Batten K, et al: A
targeted RNAi screen of the breast cancer genome identifies KIF14
and TLN1 as genes that modulate docetaxel chemosensitivity in
triple-negative breast cancer. Clin Cancer Res. 19:2061–2070. 2013.
View Article : Google Scholar
|
|
4
|
Zheng WY, Kang YY, Li LF, et al: Levels of
effectiveness of gene therapies targeting survivin and its splice
variants in human breast cancer cells. Drug Discov Ther. 5:293–238.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ashihara E: RNA interference for cancer
therapies. Gan To Kagaku Ryoho. 37:2033–2041. 2010.PubMed/NCBI
|
|
6
|
Liu JL, Wei W, Tang W, et al: Silencing of
lysyl oxidase gene expression by RNA interference suppresses
metastasis of breast cancer. Asian Pac J Cancer Prev. 13:3507–3511.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Timoshenko AV, Chakraborty C, Wagner GF,
et al: COX-2-mediated stimulation of the lymphangiogenic factor
VEGF-C in human breast cancer. Br J Cancer. 4:1154–1163. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dhakal HP, Naume B, Synnestvedt M, et al:
Expression of cyclooxygenase-2 in invasive breast carcinomas and
its prognostic impact. Histol Histopathol. 27:1315–1325.
2012.PubMed/NCBI
|
|
9
|
Troisi R, Altantsetseg D, Davaasambuu G,
et al: Breast cancer incidence in Mongolia. Cancer Causes Control.
23:1047–1053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chuang E, Paul C, Flam A, et al: Breast
cancer subtypes in Asian-Americans differ according to Asian ethnic
group. J Immigr Minor Health. 14:754–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engebraaten O, Moen Vollan HK and
Børresen-Dale AL: Triple-Negative Breast Cancer and the Need for
New Therapeutic Targets. Am J Pathol. pii: S0002–S9440,
00461–00466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Los Santos JF, Cantor A, Amos KD, et
al: Magnetic resonance imaging as a predictor of pathologic
response in patients treated with neoadjuvant systemic treatment
for operable breast cancer. Translational Breast Cancer Research
Consortium trial 017. Cancer. 119:1776–1183. 2013.
|
|
13
|
Brim RL and Pearson SD: The use and
reporting of patient-reported outcomes in phase III breast cancer
trials. Clin Trials. 10:243–249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arthur DW, Vicini FA, Todor DA, et al:
Contura Multi-Lumen Balloon breast brachytherapy catheter:
comparative dosimetric findings of a phase 4 trial. Int J Radiat
Oncol Biol Phys. 86:264–269. 2013. View Article : Google Scholar
|
|
15
|
Holmes MD, Chen WY, Schnitt SJ, et al:
COX-2 expression predicts worse breast cancer prognosis and does
not modify the association with aspirin. Breast Cancer Res Treat.
130:657–662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh AK, Parshad R, Pasi S, et al:
Prognostic significance of cyclooxygenase-2 and response to
chemotherapy in invasive ductal breast carcinoma patients by real
time surface plasmon resonance analysis. DNA Cell Biol. 30:801–807.
2011. View Article : Google Scholar
|
|
17
|
Bennett A, Berstock DA, Carroll MA, et al:
Breast cncer, its recurrence, and patient survival in relation to
tumor prostaglandins. Adv Prostaglandin Thromboxane Leukot Res.
12:299–302. 1983.PubMed/NCBI
|
|
18
|
Spizzo G, Gastl G, Wolf D, et al:
Correlation of COX-2 and Ep-CAM over expression in human invasive
breast cancer and its impact on survival. Br J Cancer. 88:574–578.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Denkert C, Winzer KJ and Hauptmann S:
Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast
Cancer. 4:428–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dhakal HP, Naume B, Synnestvedt M, et al:
Expression of cyclooxygenase-2 in invasive breast carcinomas and
its prognostic impact. Histol Histopathol. 27:1315–1325.
2012.PubMed/NCBI
|
|
21
|
Ristimäki A, Sivula A, Lundin J, et al:
Prognostic significance of elevated cyclooxygenase-2 expression in
breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
22
|
Oliveira VM, Piato S and Silva MA:
Correlation of cyclooxygenase-2 and aromatase immunohistochemical
expression in invasive ductal carcinoma, ductal carcinoma in situ,
and adjacent normal epithelium. Breast Cancer Res Treat.
95:235–241. 2006. View Article : Google Scholar
|
|
23
|
Takafuji VA, Evans A, Lynch KR and Roche
JK: PGE(2) receptors and synthesis in human gastric mucosa:
perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids.
66:71–81. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khor LY, Bae K, Pollack A, et al: COX-2
expression predicts prostate-cancer outcome: analysis of data from
the RTOG 92-02 tria1. Lancet Oncol. 8:912–920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pazhang Y, Ahmadian S, Javadifar N, et al:
COX-2 and survivin reduction may play a role in berberine-induced
apoptosis in human ductal breast epithelial tumor cell line. Tumour
Biol. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh B and Lucci A: Role of
cyclooxygenase-2 in breast cancer. J Surg Res. 108:173–179. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sivula A, Talvensaari-Mattila A, Lundin J,
et al: Association of cyclooxygenase-2 and matrix
metalloproteinase-2 expression in human breast cancer. Breast
Cancer Res Treat. 89:215–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uefuji K, Ichikura T and Mochizuki H:
Cyclooxygenase-2 expression is related to prostagland in
biosynthesis and angiogenes is in gastric cancer. Clin Cancer Res.
6:135–138. 2000.PubMed/NCBI
|
|
29
|
Surowiak P, Materna V, Matkowski R, et al:
Relationship between the expression of cyclooxygenase-2 and
MDR1/P2glycoprotein in invasive breast cancers and their prognostic
significance. Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kundu N, Smyth MJ, Samsel L, et al:
Cyclooxygenase inhibitors block cell growth, increase ceramide and
inhibit cell cycle. Breast Cancer Res Treat. 76:57–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salhab M, Singh-Ranger G, Mokbel R, et al:
Cyclooxygenase-2 mRNA expression correlates with aromatase
expression in human breast cancer. J Surg Oncol. 96:424–8. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Basu GD, Pathangey LB, Tinder TL, et al:
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells
in an in vivo model of spontaneous metastatic breast cancer. Mol
Cancer Res. 2:632–642. 2004.PubMed/NCBI
|
|
33
|
O’Mahony CA, Beauchamp RD, Albo D, et al:
Cyclooxygenase 2 alters transforming growth factor β1 response
during intestinal tumorigenesis. Surgery. 126:364–370. 1999.
|
|
34
|
Orlov SN, Thorin-Trescases N, Dulin NO, et
al: Activation of cAMP signaling transiently inhibits apoptosis in
vascular smooth muscle cells in a site upstream of caspase-3. Cell
Death Differ. 6:661–672. 1999. View Article : Google Scholar
|
|
35
|
Cao Y, Pearman AT, Zimmerman GA, et al:
Intracellular unesterified arachidonic acid signals apoptosis. Proc
Natl Acad Sci USA. 7:11280–1128. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao Y and Prescott SM: Many actions of
cyclooxygenase-2 in cellular dynamics and in cancer. J Cell
Physiol. 190:279–286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yousif S, Chaves C, Potin S, et al:
Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier
following a subchronic morphine treatment is mediated through
NMDA/COX-2 activation. J Neurochem. 123:491–503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jana D, Sarkar DK, Maji A, et al: Can
cyclo-oxygenase-2 be a useful prognostic and risk stratification
marker in breast cancer? J Indian Med Assoc. 110:429–433. 2012.
|
